Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis

Jean-Philippe Collet1, MD, PhD; Mathieu Kerneis1, MD; Benoît Lattuca2, MD; Yan Yan1, MD; Guillaume Cayla2, MD, PhD; Johanne Silvain1, MD, PhD; Frédéric Lapostolle3, MD, PhD; Patrick Ecollan4, MD; Abdourahmane Diallo5, PhD; Eric Vicaut5, MD, PhD; Christian W. Hamm6, MD, PhD; Arnoud W. van ‘t Hof7, MD; Gilles Montalescot1*, MD, PhD; for the ATLANTIC Investigators

1. Sorbonne Université Paris 6, ACTION Study Group, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France; 2. Department of Cardiology, CHU Caremeau, Université de Montpellier, ACTION Study Group, Nimes, France; 3. SAMU 93 Hôpital Avicenne, Bobigny, France; 4.

Aims: The aim of the study was to examine the main results of the ATLANTIC trial in patients with ST-elevation myocardial infarction (STEMI), randomised to pre- versus in-hospital ticagre

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

adjunctive pharmacotherapyclinical trialdrug-eluting stentelderly (>75)stemi

Coronary interventionsSTEMI

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Clinical significance of concordance or discordance between fractional flow reserve and coronary flow reserve for coronary physiological indices, microvascular resistance, and prognosis after elective percutaneous coronary intervention